TREND OF MDR-TB IN KIRKUK- IRAQ-A 10 YEARS’ EXPERIENCE AND CHALLENGES

Authors

  • Ahmed Anwer Abduallah Consultancy clinical for chest and Respiratory disease -B.Sc., Medical technology in medical laboratory technology, Kirkuk Technical College, Northern Technical University. -Higher Diploma in Pathological Analyses Tikrit University, College of Science/ Department of Biology
  • Suhaila Shamseeden Tahir Consultancy clinical for chest and Respiratory disease
  • Mohammad Abdulaziz Kadir Prof Dr. Imam Jaafar Al-Sadiq University

Keywords:

MDR-TB, Kirkuk- Iraq

Abstract

Tuberculosis is still regarded as one of major public health burden worldwide, and the emergence of multi-drug resistant TB which is defined by resistance to both Isoniazid (INH) and Rifampicin (R) with or without resistance together drug; is adding problems to public health across the continents.(1),(2) The probable causes of increasing the prevalence of multi-drugs resistance (MDR) may be attributed to the emergence of human immunodeficiency virus (HIV), poverty, migration narcotic abuse and displacement following wars, finally the poor performance of National Tuberculosis Program Strategy (NTPS) may be one of the contributing factors, as irregular treatment is worse than no treatment of initial Tuberculosis (TB) cases.(3),(4) Iraq is one of Eastern Mediterranean Region Organization (EMRO) countries and it has intermediate to relatively high burden of TB rate (651100000).(3) Although drug resistance to antibiotics is a natural phenomenon, but in case of TB it is regarded as manmade, which is attributed to interrupted treatment and poor health serves, here, it is crucial to explore types of drug resistance to anti TB, actually two important patterns of drug resistance had rayed attention, they are the multidrug resistant (MDR) and extensively drug resistant (XDR). MDR being resistant to at least INH and Rifampicin, while (XDR) is defined as MDR TB with resistance to at least aflouroquinolone and one-second line injectable agent (amikacin, kanamycin and / or caprcomycin).(5),(6)

References

1-TB India DOTS plus Guidelines 2012, RNTCP

status Report. (2010).

2-Kants, Maurya AK, Kushwaha RA, et al.

Multidrug-resistant tuberculosis. An Iatrogenic

problem. Biosu-Trend, 2010; 4: 48-55.

3-WHO reporet 2009. Global Tuberculosis

Control: epidemiology, Strategy, financing.

WHO/HTM/TB/ 2009. 411 Geneva. 2009.

4-First insight into the drug resistance pattern

of Mycobacterium tuberculosis in Dohuk Iraq:

using spoligtyping and MRUVNTR to

characterize MDR strains. Merza M A, Farnia P,

Salih A, et al. Journal of Infection and Public

Health, 2011: 4; 41-47.

5-Gandhi NR, Nunn P, Dheda K, et al.

Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global

control of tuberculosis. lancet 375, (2010):

-1843.

6-Johnston JC, Shahidi NC, Sadatsafavi M, et

al. Treatment outcomes of multi-drug resistant

tuberculosis: a systematic review and metaanalysis, PLOS One 4. (2009) e 614.

7-Schaberg T, Reichert B, Schulin T, et al.

Rapid drug Susceptibility testing

Mycobacterium tuberculosis using conventional

solid media. EurRespir. J. (1995); 8: 1688-93.

8-WHO. Global Tuberculosis Report. Geneva.

(2016).

9-WHO. Eleventh meeting of the regional

Green Light committee for the Eastern

Mediterranean, (2019).

10-Wold Health Organization. Global Health

estimates 2016. Death by cause, age, sex, by

country and by region, 2000-2016. Geruva,

WHO.2018.

11-WHO. Guidelines for surveillance of drug

resistance Tuberculosis. 4th. Ed. Geneva. 2021.

12-WHO. Global Tuberculosis Report. 2012

13-Maurya AK, Singh AK, Kumar M, et al.

Changing patterns and trends of multidrugresistant tuberculosis at refer Center in

Northern India: A 4- year experience IndianJournal of Medical microbiology; 2013, 31 41-

14-Dunachie S, Chamnan P, The double

burden of diabetes and global infection in low

and middle- income countries. Trans R Soc

Trop Med Hyg. 2019; 113: 56- 64.

15-Shenoi S, Friedland G. Extensively drug

resistant tuberculosis: a new face to an old

pathogen. Annu Rev Med. 2009; 60: 307- 20.

16-Seddon JA, Hesseling CA, Willemse M, et

al. Culture. Confirmed MDR tuberculosis in

children clinical feature, treatment, and

outcome. Clininfe Dis J. 2012; 54 (2): 157- 66.

17-Jenkns HE, Year MC. The burden of multidrug resistant tuberculosis in children. Int J

Tuber lung Dise. 2018; 22 (5): 3- 6.

18-Al- Obaidy MW. A prevalence of drugresistance previously treated Tuberculosis

patient in Baghdad. The Iraqi postgraduate.

Medical Journal. 2013; 12: 626- 631.

19-Mohammed Kh A, KhudharCh S, Al- Rabeai

DB. Prevalence and drug resistance pattern of

Mycobacterium tuberculosis isolated from

Tuberculosis patients in Basrah, Iraq. Polish

Journal of Microbiology. 2022; 71 (2): 205-

20-Kapata N, KapataPch, Bates M, et al.

Multidrug- resistant tb in Zambia: Review of

national data from 2000- 2011. Tropical

medicine and International Health. 2011

(11); 1386-1391.

21-Faye LM, Hosu MC, Iruedo J, et al.

Treatment outcomes and Associated factors

among tuberculosis patients from selected

Rural Eastern Cape Hospital. An Am

bidirectional study Tropical medicine and

Infectious disease 2023; 8: 315.

22-WHO. Summary report on the Eleventh

meeting of the regional Green Light

Committee for the Eastern Mediterranean.

Pakistan. Pp- 5.

23-Health Department: Republic of South

Africa. Management of Rifampicin Resistant

Tuberculosis. A clinical Reference Guide. 2019.

TB booklet 0220 VII, indd3.

24-Akalu TY, Clement AC, Wolde H and Alene

KA. Economic burden of multi; drug- resistant

tuberculosis on patients and households: A

global systematic revieal and meta- analysis

Scientific Report Nature Port Polio, 2023; 13:

Lecai J, Mijiti P, Chuangyue H, et al.

Treatment outcome of multi- resistant

tuberculosis patients receiving ambulatory

treatment in Shenzhen, China: a retrospective

cohort study. Frontiers in Public Health. 2023.

DOI. 10. 3389/ f pubh. 2023. 1134934.

Oladimeji O, Atiba BP, Anyiam FE, et al.

Gender and Drug-resistant tuberculosis in

Nigeria. Tropical Medicine and Infectious

Diseases. 2023: 8; 104

Downloads

Published

2024-07-19

How to Cite

Ahmed Anwer Abduallah, Suhaila Shamseeden Tahir, & Mohammad Abdulaziz Kadir. (2024). TREND OF MDR-TB IN KIRKUK- IRAQ-A 10 YEARS’ EXPERIENCE AND CHALLENGES. World Bulletin of Public Health, 36, 53-65. Retrieved from https://scholarexpress.net/index.php/wbph/article/view/4472

Issue

Section

Articles